| Previous Close | 13.85 |
| Open | 14.00 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 13.85 - 14.50 |
| 52 Week Range | 8.51 - 17.20 |
| Volume | 347,661 |
| Avg. Volume | 670,873 |
| Market Cap | 705.82M |
| Beta | 2.05 |
| PE Ratio (TTM) | 195.95 |
| EPS (TTM) | 0.07 |
| Earnings Date | Aug 2, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
Capital Cube•7 days agoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Cytokinetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
- Capital Cube•13 days ago
ETFs with exposure to Cytokinetics, Inc. : July 11, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytokinetics, Inc. Here are 5 ETFs with the largest exposure to CYTK-US. Comparing the performance and risk of Cytokinetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- GlobeNewswire•19 days ago
Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA
SOUTH SAN FRANCISCO, Calif., July 05, 2017-- Cytokinetics, Inc. today announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort ...
